The operating revenue of 136 listed pharmaceutical companies in the first half of the year was RMB 155.194 billion, up 27.98% year on year

2013-09-04 source: Biovalley this week is a week for major listed pharmaceutical companies to intensively issue semi annual reports Although the total number of listed pharmaceutical companies accounts for a very low proportion of the overall pharmaceutical companies, because the information of listed pharmaceutical companies is publicly disclosed, it is undoubtedly a good reference and reference for the study of the overall pharmaceutical market The operating performance of the pharmaceutical sector is better than the overall level of Shanghai and Shenzhen stock markets In the first half of 2013, listed companies disclosed their strategies According to the (New) industry classification of the CSRC, according to data statistics, 136 pharmaceutical companies achieved operating revenue of 15.5194 billion yuan in the first half of 2013, an increase of 27.98% year-on-year; net operating profit of 21.692 billion yuan, an increase of 23.68% year-on-year Among them, there are four enterprises with a year-on-year growth of more than 100% in operating revenue, achieving a year-on-year growth of: * ST Guoyao: 875.78%, shutaishen: 147.97%, Zhongheng group: 122.95%, HongRi pharmaceutical: 103.62% In addition, 11 companies realized a year-on-year increase in operating revenue of more than 50% in the first half of 2013: Dongbao biological, Zhongzhu holding, Duyiwei, Lianhuan pharmaceutical, Yuheng pharmaceutical, Yiling pharmaceutical, Rhine biological, Baiyunshan, Huaren pharmaceutical, dong'a-jiao and Changshan pharmaceutical There are 18 companies with a year-on-year income growth of 30% - 50%, including Haizheng pharmaceutical, Daan gene, Yongsheng investment and taiantang, among which the fast growth of Haizheng pharmaceutical in the first half of the year is mainly due to the high income growth of the subsidiary of Haizheng Pfizer According to the company's financial report data, the sales revenue of Zhengyao drugs reached 1.624 billion yuan, a year-on-year increase of 20.69%, and that of non Haizheng drugs reached 2.589 billion yuan, a year-on-year increase of 70.62% The operating revenue of 59 companies increased by 10% - 30% year on year, including Jilin Aodong, Zhifei biology, Fosun medicine, Tishi, wohua medicine, Huabei Pharmaceutical (27.68%), zoelli Pharmaceutical (27.50%), Tonghua Dongbao (27.33%) and Zhongsheng Pharmaceutical (26.78%) In addition, there are 21 companies with a year-on-year growth of 0% - 10% in revenue, including Laimei Pharmaceutical (9.5%), Yibai Pharmaceutical (9.34%), Jingxin Pharmaceutical (08.77%), Guilin Sanjin (, 8.41%) and other companies Among them, the growth of Laimei pharmaceutical revenue mainly depends on specialty drugs According to the financial report data, in the first half of 2013, the total income of anti infection, specialty drugs and infusion was 285 million, accounting for 79.96% of the total income, of which the income of specialty drugs was 77.48 million yuan, an increase of 37.15% year on year However, in the first half of 2013, the operating revenue of 22 companies decreased compared with the same period of last year Among them, the four companies, Sanjing pharmaceutical, Renhe pharmaceutical, Fengyuan Pharmaceutical (000153 ( In this regard, Sanjing pharmaceutical analysis is that the company's channel consolidation and inventory digestion are still continuing, resulting in a downward trend in the revenue of its leading product business According to statistics, 136 pharmaceutical companies achieved a total net profit of 17.928 billion yuan in the first half of 2013, a year-on-year increase of 28.66% The industry operation has maintained a stable development momentum Among them, 14 companies achieved net profit growth of more than 100% They are * ST Guoyao, Jiaying pharmaceutical, Lingrui pharmaceutical and Taiji group, ）, Duyiwei, Kangzhi pharmaceutical, Jinyu group, Rhine biology, Jincheng pharmaceutical, Huabei pharmaceutical, guangyuyuan, Guonong science and Technology), Tianmu pharmaceutical and Guangji pharmaceutical Among them, St Sinopharm, currently facing the situation of controlling shares, showed that the company's revenue in the first half of the year was 41.5656 million yuan, an increase of 875.78% on a year-on-year basis, and the net profit attributable to the shareholders of the listed company was 1459.95% In the same period of last year, it was a loss of 1.9532 million yuan and a basic earnings per share of 0.075 yuan The company said that it continued to increase the disposal of losses and idle assets, and sold the shares of Wuhan yekaitai pharmaceutical chain Co., Ltd and Wuhan Lexin Pharmaceutical Co., Ltd in the reporting period, gradually reducing losses In the first half of 2013, 12 companies, including Beijing new pharmaceutical, Northeast Pharmaceutical, jiankangyuan, Dongbao biology, Lukang medicine, Changchun hi tech, xinlitai, * ST biochemistry, HongRi medicine, Tiantan biology, Tonghua Dongbao and Fosun medicine, realized a year-on-year increase in operating revenue of more than 50% There are 24 companies with a year-on-year increase of 30% - 50% in net profit, including Da'an gene, sunwater and Shanghai Furen, among which Da'an gene Zhongbao shows that in the first half of 2013, the company's operating revenue was 381 million yuan, a year-on-year increase of 45.5%; the operating profit was 59.48 million yuan, a year-on-year increase of 48%, 9%, with a net profit of 56.88 million yuan, a year-on-year increase of 49.3%; in addition, the company expects a net profit growth rate of 50-80% in the first three quarters of 2013 49 companies achieved a year-on-year net profit growth of 10% - 30%, including Kangyuan Pharmaceutical (29.76%), Xiangxue Pharmaceutical (29.54%), Lidman (28.84%), Yabao Pharmaceutical (28.57%), Qizheng Tibetan Pharmaceutical (28.00%), Shanghai Laishi (27.43%), Kehua biology, zoelli Pharmaceutical (26.05%) and Zhongzhu holding (25.38%) However, there are also some companies whose performance is regrettable In particular, the net profit of the three companies, namely Sihuan pharmaceutical, Sihuan biology and Sanjing pharmaceutical, has plummeted by more than 100% year on year, with losses of 2065800 yuan, 1181400 yuan and 33551200 yuan respectively In addition, the net profits of 34 companies including Haixiang pharmaceutical, Xinhua Pharmaceutical and Furui Co., Ltd decreased to some extent year on year The decrease was 96.41% - 1.37%.